3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
| Status: | Recruiting |
|---|---|
| Conditions: | Cancer, Brain Cancer, Blood Cancer, Lymphoma, Hematology, Leukemia |
| Therapuetic Areas: | Hematology, Oncology |
| Healthy: | No |
| Age Range: | 18 - 120 |
| Updated: | 2/14/2019 |
| Start Date: | September 2009 |
| End Date: | April 2021 |
Use of [F-18] FLT for Imaging With Positron Emission Tomography (PET)
RATIONALE: Diagnostic procedures, such as 3'-deoxy-3'-[18F] fluorothymidine (FLT) PET
imaging, may help find and diagnose cancer. It may also help doctors predict a patient's
response to treatment and help plan the best treatment.
PURPOSE: This phase I trial is studying FLT PET imaging in patients with cancer.
imaging, may help find and diagnose cancer. It may also help doctors predict a patient's
response to treatment and help plan the best treatment.
PURPOSE: This phase I trial is studying FLT PET imaging in patients with cancer.
OBJECTIVES:
Primary
- Evaluate the use of 3'-deoxy-3'-[18F] fluorothymidine (FLT) positron emission tomography
(PET) imaging to measure tumor proliferation and the DNA synthetic pathway (thymidine
kinase levels) in patients with cancer.
Secondary
- Determine the efficacy of FLT PET imaging in detecting lesions and estimating response
to treatment.
OUTLINE: Patients undergo up to four 3'-deoxy-3'-[18F] fluorothymidine positron emission
tomography imaging procedures.
Primary
- Evaluate the use of 3'-deoxy-3'-[18F] fluorothymidine (FLT) positron emission tomography
(PET) imaging to measure tumor proliferation and the DNA synthetic pathway (thymidine
kinase levels) in patients with cancer.
Secondary
- Determine the efficacy of FLT PET imaging in detecting lesions and estimating response
to treatment.
OUTLINE: Patients undergo up to four 3'-deoxy-3'-[18F] fluorothymidine positron emission
tomography imaging procedures.
DISEASE CHARACTERISTICS:
- Meets one of the following criteria:
- Histologically confirmed solid tumor or hematologic malignancy
- Awaiting biopsy or surgery for cancer evaluation of a mass detected on exam or
standard imaging
PATIENT CHARACTERISTICS:
- Able to lie still in the PET scanner
- Girth and weight must be suitable to enter the gantry
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY:
- Not specified
We found this trial at
1
site
Barbara Ann Karmanos Cancer Institute Karmanos is based in southeast Michigan, in midtown Detroit, and...
Click here to add this to my saved trials
